LUC00055I2 - - Google Patents

Download PDF

Info

Publication number
LUC00055I2
LUC00055I2 LU00055C LUC00055C LUC00055I2 LU C00055 I2 LUC00055 I2 LU C00055I2 LU 00055 C LU00055 C LU 00055C LU C00055 C LUC00055 C LU C00055C LU C00055 I2 LUC00055 I2 LU C00055I2
Authority
LU
Luxembourg
Prior art keywords
warm
treatment
allergy
mastocytosis
angioedema
Prior art date
Application number
LU00055C
Other languages
English (en)
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33539193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00055(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of LUC00055I1 publication Critical patent/LUC00055I1/fr
Publication of LUC00055I2 publication Critical patent/LUC00055I2/fr
Publication of LUC00055I9 publication Critical patent/LUC00055I9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU00055C 2003-06-18 2017-12-12 LUC00055I9 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47957503P 2003-06-18 2003-06-18
PCT/EP2004/006562 WO2004112794A2 (fr) 2003-06-18 2004-06-17 Nouvelle utilisation de derives de staurosporine
EP04740016A EP1638574B1 (fr) 2003-06-18 2004-06-17 Nouvelle utilisation de derives de staurosporine

Publications (3)

Publication Number Publication Date
LUC00055I1 LUC00055I1 (fr) 2017-12-14
LUC00055I2 true LUC00055I2 (fr) 2018-02-21
LUC00055I9 LUC00055I9 (fr) 2022-11-09

Family

ID=33539193

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00055C LUC00055I9 (fr) 2003-06-18 2017-12-12

Country Status (23)

Country Link
US (2) US8575146B2 (fr)
EP (1) EP1638574B1 (fr)
JP (2) JP5057780B2 (fr)
CN (2) CN101164539A (fr)
AT (1) ATE464052T1 (fr)
AU (1) AU2004248909B2 (fr)
BE (1) BE2017C067I2 (fr)
BR (1) BRPI0411563B8 (fr)
CA (2) CA2785950A1 (fr)
CY (2) CY1110179T1 (fr)
DE (1) DE602004026578D1 (fr)
DK (1) DK1638574T3 (fr)
ES (1) ES2344700T3 (fr)
FR (1) FR17C1063I2 (fr)
HU (1) HUS000503I2 (fr)
LU (1) LUC00055I9 (fr)
MX (1) MXPA05013722A (fr)
NL (1) NL300917I2 (fr)
PL (1) PL1638574T3 (fr)
PT (1) PT1638574E (fr)
SI (1) SI1638574T1 (fr)
TW (1) TWI324604B (fr)
WO (1) WO2004112794A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT
WO2005115385A1 (fr) * 2004-05-24 2005-12-08 Ab Science Utilisation d'inhibiteurs de c-kit pour le traitement de l'acne
JP5704785B2 (ja) * 2004-07-19 2015-04-22 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫抑制のためのｆｌｔ３阻害剤
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
GB0419159D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
CN103638028A (zh) * 2005-05-02 2014-03-19 诺瓦提斯公司 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
WO2007010014A2 (fr) * 2005-07-20 2007-01-25 Peter Valent Compositions pour le traitement de mastocytose systemique
JP5308820B2 (ja) * 2005-11-14 2013-10-09 ウニヴェルジテート・チューリッヒ 胞巣状横紋筋肉腫に使用するためのスタウロスポリン誘導体
WO2009092442A1 (fr) * 2008-01-23 2009-07-30 Universidad De Barcelona Traitement de l'hypertension portale et d'états apparentés par une inhibition combinée des voies de signalisation de vegf et pdgf
EP2662078A1 (fr) 2010-11-10 2013-11-13 National Jewish Health Procédés pour traiter des états allergiques
EP3873462A4 (fr) 2018-11-01 2022-08-03 Syros Pharmaceuticals, Inc. Méthodes de traitement du cancer chez des patients identifiés par biomarqueurs avec des inhibiteurs non covalents de la kinase cycline-dépendante 7 (cdk7)
WO2020097261A1 (fr) * 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nouvelles compositions et nouveaux procédés de traitement de globinopathies
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
KR102805013B1 (ko) * 2022-03-15 2025-05-09 국립해양생물자원관 스트렙토마이세스 속 snc087 균주 또는 이로부터 분리한 스타우로스포린을 유효성분으로 포함하는 비용종 예방 또는 치료용 약학 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639455A (en) 1984-10-02 1987-01-27 Key Pharmaceuticals, Inc. Means of aiding in the prevention of sudden infant death syndrome
JPH0826037B2 (ja) * 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
CA2046801C (fr) 1990-08-07 2002-02-26 Peter D. Davis Pyrroles substitues
DE69229490T2 (de) * 1991-05-09 2000-02-17 Neurim Pharmaceuticals (1991) Ltd., Tel Aviv Melatonin enthaltende Arzneimittel
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
AU721942B2 (en) * 1996-06-25 2000-07-20 Cephalon, Inc. Use of K-252A derivative for the treatment of peripheral or central nerve disorders, and cytokine overproduction
US6093740A (en) 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
WO1999062537A1 (fr) 1998-06-04 1999-12-09 The Rockefeller University Procedes et agents permettant la modulation de la reponse immunitaire et de l'inflammation par modulation des proteines membranaires des monocytes et des cellules dendritiques
GB9903547D0 (en) * 1999-02-16 1999-04-07 Novartis Ag Organic compounds
RU2275373C2 (ru) * 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
GB0108606D0 (en) 2001-04-05 2001-05-23 Novartis Ag Organic compounds
US20030091974A1 (en) * 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
PT1441737E (pt) * 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
JPWO2004091663A1 (ja) 2003-04-18 2006-07-06 協和醗酵工業株式会社 神経再生薬
EP1637161A4 (fr) 2003-04-22 2007-06-27 Astellas Pharma Inc REMEDE CONTRE DES MALADIES CEREBRALES NEURODEGENERATIVES UTILISANT UN AGONISTE DES PPAR [delta]
TWI324604B (en) * 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
SI1686997T1 (sl) 2003-11-18 2009-08-31 Novartis Ag Inhibitorji mutantne oblike KIT

Also Published As

Publication number Publication date
TWI324604B (en) 2010-05-11
DK1638574T3 (da) 2010-08-02
NL300917I1 (nl) 2017-12-12
US8575146B2 (en) 2013-11-05
CN1805749A (zh) 2006-07-19
MXPA05013722A (es) 2006-03-08
ES2344700T3 (es) 2010-09-03
JP2006527727A (ja) 2006-12-07
FR17C1063I1 (fr) 2018-02-16
SI1638574T1 (sl) 2010-08-31
JP2012144572A (ja) 2012-08-02
CY1110179T1 (el) 2015-01-14
CA2785950A1 (fr) 2004-12-29
WO2004112794A3 (fr) 2005-06-16
US20130289018A1 (en) 2013-10-31
US20070299049A1 (en) 2007-12-27
HUS000503I2 (hu) 2021-03-29
JP5057780B2 (ja) 2012-10-24
CY2017048I2 (el) 2018-09-05
WO2004112794A2 (fr) 2004-12-29
PL1638574T3 (pl) 2010-09-30
EP1638574A2 (fr) 2006-03-29
FR17C1063I2 (fr) 2019-05-03
NL300917I2 (nl) 2018-01-09
CN101164539A (zh) 2008-04-23
TW200512213A (en) 2005-04-01
BRPI0411563B1 (pt) 2019-09-24
DE602004026578D1 (de) 2010-05-27
PT1638574E (pt) 2010-07-14
LUC00055I9 (fr) 2022-11-09
CA2527703A1 (fr) 2004-12-29
AU2004248909A1 (en) 2004-12-29
EP1638574B1 (fr) 2010-04-14
CN100457111C (zh) 2009-02-04
ATE464052T1 (de) 2010-04-15
CA2527703C (fr) 2012-10-23
HUS1700053I1 (hu) 2018-01-29
CY2017048I1 (el) 2018-09-05
HK1095519A1 (zh) 2007-05-11
AU2004248909B2 (en) 2008-05-08
BRPI0411563A (pt) 2006-08-01
LUC00055I1 (fr) 2017-12-14
BRPI0411563B8 (pt) 2021-05-25
BE2017C067I2 (fr) 2023-08-09

Similar Documents

Publication Publication Date Title
FR17C1063I1 (fr)
DK1611088T3 (da) Hydroxymater som terapeutiske midler
WO2003066579A3 (fr) Nouveaux hydroxamates bicycliques servant d'inhibiteurs de histone desacetylase
EA200971053A1 (ru) Способы лечения кожных язв
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
EA201390353A1 (ru) Производное пиразолохинолина
EP1539234A4 (fr) Methodes de prevention ou de traitement de malignites cellulaires par administration d'antagonistes de cd2
WO2000064441A3 (fr) Medicament
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE520668T1 (de) Sigmarezeptor-inhibitoren
PL1656348T3 (pl) Pochodne acetylenu jako inhibitory deacetylazy histonowej
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
WO2008070010A3 (fr) Rétablissement après une attaque
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
GB2427405A (en) Novel hydroxamates as therapeutic agents
WO2000076500A3 (fr) Compound for use as a medicament for treatment of disorders involving bronchocontraction
TH401002069A (th) การใช้แบบใหม่ของอนุพันธ์สเทาโรสพอรีน
SE0103539D0 (sv) New Use